AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of "Moderate Buy" from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten analysts that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $35.88.

ANAB has been the subject of a number of research analyst reports. Wolfe Research assumed coverage on AnaptysBio in a report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 target price for the company. Wells Fargo & Company raised their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Guggenheim raised their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research note on Tuesday, March 4th.

AnaptysBio Stock Up 0.1 %

ANAB opened at $19.59 on Friday. The firm has a market cap of $579.35 million, a PE ratio of -3.22 and a beta of -0.20. The business has a fifty day simple moving average of $18.63 and a 200-day simple moving average of $18.59. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. On average, equities research analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a stock repurchase plan on Monday, March 24th that allows the company to buyback $75.00 million in shares. This buyback authorization allows the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE boosted its holdings in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 979 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of AnaptysBio by 9,778.9% in the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,858 shares during the period. Tower Research Capital LLC TRC grew its position in AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in AnaptysBio during the fourth quarter valued at about $40,000. Finally, AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 4,237 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.